Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Xiangxue Pharma Developing Alzheimer’s Treatment

publication date: Dec 23, 2010
Xiangxue Pharmaceutical, which completed its IPO on Shenzhen’s GEM Exchange on December 15, expects to have a TCM treatment for Alzheimer’s disease on the market within three years. Wang Yonghui, Manager of Xiangxue, also disclosed plans to extend the indication of its major product, Anti-Virus Oral Liquid, to include conjunctivitis and HFMD (hand, foot and mouth) diseases. More details....

Stock Symbol: (SHEZ: 300147)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital